Dr. Spigel Discusses MPDL3280A Development in Lung Cancer
David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses current trials involving MPDL3280A in lung cancer.
David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses current trials investigating the anti-PD-L1 antibody MPDL3280A in lung cancer.
There are a number of ongoing trials investigating MPDL3280A in lung cancer, following the presentation of promising data from a phase I trial investigating the drug in lung cancer at last year’s ASCO. One trial is looking at MPDL3280A versus docetaxel in unselected patients. However, there are also single cohort studies where patients receive the drug in PD-L1 positive tumors, Spigel says.
Two of these studies are designed to enroll patients in the first-line setting, second-line and beyond, and in patients with CNS metastasis. Spigel is hopeful that as the single-arm studies mature and the randomized registration trials mature, new options will be available in lung cancer.
<<<
